EGFR and non-small cell lung carcinoma: The Oncomine Lung cfDNA Assay can be used to identify plasma EGFR mutations in patients with NSCLC, although further large-scale studies are needed to evaluate the analytical validity for other types of aberrations and genes using clinical samples.